Abstract
The recent identification of the sequences of the peptides derived from a number of human melanomaassociated antigens has presented opportunities for developing a specific-peptide-based vaccine in this form of cancer. Since antigen-presenting cells (APC) play a crucial role in the induction of the T-cell-mediated immune response, we examined whether or not ex vivo cultured APC, bearing the appropriate MHC restricting elements, when pulsed with a relevant melanoma-specific cytotoxic-T-lymphocyte(CTL)-determined peptide, can present the peptide to the CTL. Here we show that a population of cells, derived from the monocyte/macrophage lineage from peripheral blood and grown in granulocyte/macrophage-colony-stimulating factor, exhibit many essential characteristics of “professional” APC (dendritic-type morphology with a proportion of the population, the B7 molecule, and high levels of MHC class I and class II molecules, CD11b and CD54 molecules) and are capable of efficiently presenting the nonapeptide, EADPTGHSY, encoded by the melanoma antigen MAGE-1 gene, to the MAGE-1-specific CTL clone, 82/30. These results suggest that this type of autologous ex vivo cultured population of professional APC, when pulsed with the relevant-CTL-determined peptide, can serve as a novel type of candidate vaccine for active specific immunization against HLAA1-positive patients with melanoma expressing the MAGE-1 antigen.
References
Bruggen P van der, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254: 1643–1647
Espevik T, Nissen-Meyer J (1986) A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J Immunol Methods 95: 99–103
Hansen MB, Nielsen SE, Berg K (1989) Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods 119: 203–208
Houghton AN (1994) Cancer antigens; immune recognition of self and altered self. J Exp Med 180: 347–349
Mukherji B, MacAlister TJ (1983) Clonal analysis of cytotoxic T cell response against human melanoma. J Exp Med 158: 240–246
Okino T, Chakraborty NG, Stabach P, Twardzik D, Padula SJ, Mukherji B (1993) Inhibition of interleukin-2 synthesis and interleukin-2 receptor expression on the T cells by a cell-free factor derived from a CD4+ regulatory T cell clone. Clin Immunol Immunopathol 68: 256–262
Pardoll DM (1994) Tumor antigens: a new look for the 1990s. Nature 369: 357–358
Traversari C, Bruggen P van der, Luescher IF, Lurquin C, Chomez P, Van Pel A, De Plaen E, Amar-Costesec A, Boon T (1992) A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytotoxic T lymphocytes directed against tumor antigen MZ2-E J Exp Med 176: 1453–1457
Author information
Authors and Affiliations
Additional information
This work was supported by a PHS grant CA 61398 and in part by the Lavery Cancer Research Fund
Rights and permissions
About this article
Cite this article
Yamasaki, S., Okino, T., Chakraborty, N.G. et al. Presentation of synthetic peptide antigen encoded by the MAGE-1 gene by granulocyte/macrophage-colony-stimulating-factor-cultured macrophages from HLA-A1 melanoma patients. Cancer Immunol Immunother 40, 268–271 (1995). https://doi.org/10.1007/BF01519901
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01519901